Addendum
Nivolumab (adenocarcinoma of the stomach, the gastro-oesophageal junction or the oesophagus) – 2nd Addendum to Commission A21-146
Report documents
-
Addendum
Nivolumab (adenocarcinoma of the stomach, the gastro-oesophageal junction or the oesophagus) – 2nd Addendum to Commission A21-146
Dossier assessment
First-line treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express programmed cell death ligand 1 (PD-L1, combined positive score [CPS] ≥ 5)
After addendum:
- Oesophageal adenocarcinoma: hint of considerable added benefit.
- Gastric or gastro-oesophageal junction adenocarcinoma: hint of considerable added benefit.
Additional information
Federal Joint Committee (G-BA)
2022-05-20 A G-BA decision was published.
Project details
- Project no.
- A22-44
- Commission
- Commission awarded on 12.04.2022 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Nivolumab (gastric adenocarcinoma, adenocarcinoma of the gastroesophageal junction or the oesophagus) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed